


姓名:	姜乃榕	填表日期: (YYYY/MM/DD)	2023/02/19	
單位:	腫瘤醫學部	現職職稱:	主治醫師	
Email:	njchiang@vghtpe.gov.tw	連絡電話:	8#1092	
學歷:	國立成功大學臨床醫學研究所博士/國防大學醫學系			
重要經歷:	<p>2022.3-迄今 臺北榮總腫瘤醫學部主治醫師及國家衛生研究院癌症研究所兼任助研究員級主治醫師</p> <p>2020.4-2022.2 國家衛生研究院癌症研究所助研究員級主治醫師及國立成功大學醫學院附設醫院腫瘤部主治醫師。</p> <p>2013.7-2020.3 國家衛生研究院癌症研究所及國立成功大學醫學院附設醫院內科部腫瘤血液科主治醫師。</p> <p>2010.9-2013.6 國家衛生研究院癌症研究所研究醫師及國立成功大學醫學院附設醫院內科部腫瘤血液科主治醫師。</p> <p>2008.9-2010.8 國家衛生研究院癌症研究所及國立成功大學醫學院附設醫院內科部腫瘤血液科住院醫師。</p>			
研究方向: (關鍵詞)	胰臟癌/膽道癌/胃癌/食道癌/臨床試驗			
五年內 代表著作:	<ol style="list-style-type: none"> Chueh CH, Tsai YW, Chen ZR, Shiu MN, Wen YW, Chiang NJ*. Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. <i>Pharmacoeconomics</i>. 41(3):307-319. doi:10.1007/s40273-022-01227-6, 2023. (corresponding author) Su YY*, Chiang NJ*, Chang JS, Wang YW, Shen BN, Li YJ, Hwang DY, Shan YS, Chen LT. The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan. <i>ESMO Open</i>. 8(1):100746, 2022. (*Co-first author) Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT, Chen MH. Impaired Chromatin Remodeling Predicts Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. <i>Clin Cancer Res</i>. 28(19):4248-4257, 2022. Chiang NJ, Shan YS, Li CP, Yang SH, Su YY, Chiu SZ, Bai LY, Chuang SC, Chan DC, Yen CJ, Peng CM, Chiu TJ, Chen YY, Chen JS, Chou WC. The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinoma. <i>Am J Cancer Res</i>. 12(11):5062-5073, 2022. Chiang NJ, Hou YC, Tan KT, Tsai HW, Lin YJ, Yeh YC, Chen LT, Hou YF, Chen MH, Shan YS. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma. <i>Hepatology International</i>. 16(5):1137-1149, 2022. 			

6. Su YY*, **Chiang NJ***, Li CP, Yen CJ, Yang SH, Chou WC, Chen JS, Chiu TJ, Chen YY, Chuang SC, Bai LY, Chiu CF, Peng CM, Chan DC, Chiu SC, Yang YH, Shan YS, Chen LT. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. *Front Oncol.* 12:800842, 2022. (*Co-first author)
7. Yang SH*, **Chiang NJ***, Chiu SC, Chou WC, Bai LY, Li CP, Su YY, Chiu TJ, Chuang SC, Peng CM, Chan DC, Chen JS, Yen CJ, Chen YY, Chiu CF, Chen LT, Shan YS. The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. *Am J Cancer Res.* 12(4):1884-1898, 2022. (*Co-first author)
8. Gopinathan P*, Liu CH*, **Chiang NJ***, Huang CJ, Tu HC, Hung SC, Shan YS, Lee GB. Exfoliated tumor cells in bile as a promising indicator of disease status in cholangiocarcinoma. *Sensors and Actuators B: Chemical.* 346: 130526, 2021. (***Co-first author**)
9. Chang KY, **Chiang NJ**, Wu SY, Yen CJ, Chen SH, Yeh YM, Li CF, Feng X, Wu Katherine, Amanda Johnston, John S Bomalaski, Wu BW, Gao J, Sumit K Subudhi, Ahmed O Kaseb, Jorge M Blando, Shalini S Yadav, Peter W Szlosarek, Chen LT. Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers. *Oncoimmunology.* 12;10(1):1943253, 2021.
10. Wang YL, Jhang DF, Tsai CH, **Chiang NJ**, Tsao CH, Chuang CC, Chen LT, Chang WS, Liao LD. In Vivo Assessment of Hypoxia Levels in Pancreatic Tumors Using a Dual-Modality Ultrasound/Photoacoustic Imaging System. *Micromachines (Basel).* 12(6):668, 2021.
11. **Chiang NJ**, Chen LT, Shan YS, Yeh CN, Chen MH. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. *Biomolecules.* 13;11(1):97, 2021.
12. Shiah HS*, **Chiang NJ***, Lin CC, Yen CJ, Tsai HJ, Wu SY, Su WC, Chang KY, Wang CC, Chang JY, Chen LT. Phase I dose escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors. *The Oncologist.* 26(4):e567-e579. doi:10.1002/onco.13612, 2021. (***Co-first author**)
13. Gopinathan P*, **Chiang NJ***, Wang CH, Sinha A, Tsai YC, Tu HC, Hung SC; Hsu PH, Shan YS, Lee GB. Aptamer probed isolation of circulating tumor cells in cholangiocarcinoma patients. *Sensors and Actuators B: Chemical.* 322: 128569, 2020. (***Co-first author**)
14. **Chiang NJ**, Chen MH, Yang SH, Hsu C, Yen CJ, Tsou HH, Su YY, Chen JS, Shan YS, Chen LT. Multicentre, Phase II Study of Gemcitabine and S-1 in Patients With Advanced Biliary Tract Cancer: TG1308 Study. *Liver Int.* 40(10):2535-2543, 2020.
15. **Chiang NJ**, Tsai KK, Chen JS, Yang SH, Hsiao HH, Shan YS, Chen LT. A Multicenter, Phase I/II Trial of Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine in Metastatic Pancreatic Adenocarcinoma -TCOG T1211 Study. *European Journal of Cancer.* 124: 123-130, 2020.
16. Gopinathan P*, **Chiang NJ***, Bandaru A, Sinha A, Huang WY, Hung SC, Shan YS, Lee GB. Exploring Circulating Tumor Cells in Cholangiocarcinoma Using a Novel Glycosaminoglycan Probe on a Microfluidic Platform. *Adv Healthc Mater.* 9(10): e1901875, doi: 10.1002/adhm.201901875, 2020. (***Co-first author**)

研究室成員： 呂孟倫小姐/趙素嬌小姐